Stockscreener 앱 받기
75.78
0.40%
0.30
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
Is Apogee Therapeutics Inc a good long term investmentDay Trading Setups & High Return Trading Portfolio - earlytimes.in
Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Apogee Therapeutics Inc (NASDAQ:APGE) Nasdaq today Early Biotech Stage - Kalkine Media
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
BTIG reiterates Buy rating on Apogee Therapeutics stock amid positive outlook - Investing.com
Value Recap: What technical signals suggest for Apogee Therapeutics Inc. stockMarket Activity Report & Safe Entry Zone Identification - moha.gov.vn
Apogee Therapeutics Earnings Notes - Trefis
Henderson, Apogee Therapeutics CFO, sells $120k in stock - Investing.com
Apogee Therapeutics CFO Sells 1,500 Shares - TradingView — Track All Markets
Will Apogee Therapeutics Inc. stock benefit from AI adoption2025 Winners & Losers & Weekly Top Performers Watchlists - Улправда
Apogee Therapeutics (APGE) Gets a Buy from Bank of America Securities - The Globe and Mail
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN
Apogee Therapeutics stock hits all-time high of 78.19 USD - Investing.com
Apogee Therapeutics stock hits all-time high of 78.19 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics (NASDAQ:APGE) Hits New 12-Month HighWhat's Next? - MarketBeat
Is Apogee Therapeutics Inc. stock a safe investment in uncertain markets2025 Winners & Losers & Safe Capital Growth Tips - DonanımHaber
Apogee Therapeutics (NASDAQ:APGE) Rating Increased to Strong-Buy at Stephens - MarketBeat
Market Outlook: Will Apogee Therapeutics Inc. stock benefit from AI adoptionWeekly Market Summary & Weekly Return Optimization Alerts - ulpravda.ru
Will Apogee Therapeutics Inc. stock gain from lower inflation2025 Buyback Activity & Smart Investment Allocation Insights - Улправда
Trend Recap: What insider trading reveals about Apogee Therapeutics Inc. stockMarket Movers & Fast Exit and Entry Strategy Plans - Улправда
What insider trading reveals about Apogee Therapeutics Inc. stockQuarterly Trade Summary & Technical Analysis for Trade Confirmation - Улправда
What dividend safety score for Apogee Therapeutics Inc. stockWeekly Trade Report & Risk Managed Investment Entry Signals - ulpravda.ru
How Apogee Therapeutics Inc. stock benefits from global expansionMarket Risk Summary & Daily Stock Trend Reports - Улправда
Stephens Initiates Coverage on Apogee Therapeutics With Overweight Rating, $95 Price Target - marketscreener.com
Stephens & Co. initiates coverage of Apogee Therapeutics (APGE) with overweight recommendation - MSN
How Apogee Therapeutics Inc. (APGE) Affects Rotational Strategy Timing - Stock Traders Daily
Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics Inc. $APGE Shares Sold by Braidwell LP - MarketBeat
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics CEO Sells 20,000 Shares - TradingView — Track All Markets
CEO Henderson Sells 20,000 ($1.5M) Of Apogee Therapeutics Inc [APGE] - TradingView — Track All Markets
Apogee Therapeutics (NASDAQ:APGE) Hits New 1-Year HighHere's Why - MarketBeat
Apogee Therapeutics stock reaches all-time high of 77.21 USD - Investing.com India
Apogee Therapeutics stock reaches all-time high of 77.21 USD By Investing.com - Investing.com Canada
Stempoint Capital LP Makes New Investment in Apogee Therapeutics Inc. $APGE - MarketBeat
Deutsche Bank Initiates Apogee Therapeutics at Buy With $103 Price Target - marketscreener.com
Deutsche Bank Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - Nasdaq
Apogee Therapeutics initiated with a buy at Deutsche Bank - MSN
Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank By Investing.com - Investing.com South Africa
Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank - Investing.com
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times
Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth - Yahoo Finance
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Certain Restricted Stock Units of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-DEC-2025. - marketscreener.com
Certain Stock Options of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-DEC-2025. - marketscreener.com
Apogee Therapeutics (NASDAQ:APGE) CEO Sells $3,000,400.00 in Stock - MarketBeat
Carl Dambkowski Sells 10,900 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat
Schroder Investment Management Group Boosts Stock Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Apogee Therapeutics CMO sells $817k in stock By Investing.com - Investing.com Australia
Insider Sell: Jane Henderson Sells 1,500 Shares of Apogee Therap - GuruFocus
0.57%
자본화:
|
볼륨(24시간):